FindTrial
Sign In

Effects of gene polymorphisms on lamotrigine mono therapeutic efficacy

Effects of gene polymorphisms on lamotrigine mono therapeutic efficacy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17011382
Enrollment
Unknown
Registered
2017-05-12
Start date
2017-05-20
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Treatment:Lamotrigine oral
Normal population:Nil

Sponsors

Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The Han people; 2. Aged >12 years; 3. The diagnosis of epilepsy is confirmed; 4. Using lamotrigine regularly.

Exclusion criteria

Exclusion criteria: 1. Combined with other antiepileptic drugs; 2. Combined with other drugs that effect lamotrigine; 3. Breastfeeding or pregnancy; 4. Liver or kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Lamotrigine concentration;Genotyping;—

Countries

China

Contacts

Public ContactXiaoxing Yin

Xuzhou Medical University

yinxx@xzhmu.edu.cn+86 13605218523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026